<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04332627</url>
  </required_header>
  <id_info>
    <org_study_id>B-1910/571-004</org_study_id>
    <nct_id>NCT04332627</nct_id>
  </id_info>
  <brief_title>Comparison of QoR-15 in Laparoscopic Cholecystectomy: Sugammadex vs. Neostigmine</brief_title>
  <official_title>Comparison of Quality of Recovery Score (QoR-15) According to Neuromuscular Blocking Reversal Agent in Laparoscopic Cholecystectomy: Sugammadex vs. Neostigmine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Bundang Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The quality of recovery in patients who were reversed neuromuscular blockade by using
      Sumamadex and Neostigmine in laparoscopic cholecystectomy was compared through the
      QoR(Quality of Recovery)-15 questionnaire.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Quality of Recovery questionnaire includes five details (Emotional status, Physical comfort,
      Physiological support, Physical independece, Pain), and is a proven method of reliability,
      consistency and validity for evaluating recovery from surgery and anesthesia.

      After laparoscopic cholecystectomy, patients experience various discomforts such as pain,
      nausea, vomiting, and placebo due to general anesthesia.

      Neostigmine has side effects such as crampy abdominal pain, nausea and vomiting. In addition,
      residual neuromuscular blockade was higher in neostigmine compared with sugammadex.

      Although sugammadex expected to improve patient's recovery, it is still controversial that
      sugammadex contributes to clinically meaningfull difference compared with neostigmine.

      Therefore, the aim of our study is comparison of quality of recovery through QoR-15
      questionnaire in patients who were reversed neuromuscular blockade by using sugammadex and
      neostigmine in laparoscopic cholecystectomy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 24, 2020</start_date>
  <completion_date type="Anticipated">July 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of Recovery(QoR)-15 questionnaire score</measure>
    <time_frame>preoperative 1 days to postoperative 2 days</time_frame>
    <description>the difference of QoR-15 score between preoperative and postoperative 1 and 2 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>recovery time</measure>
    <time_frame>perioperative - until 48hr</time_frame>
    <description>from injection of sugammadex or neostigmien to extubation and confirm of adequate spontaneous breathing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PACU(post-anesthesia care unit) stay time</measure>
    <time_frame>perioperative - until 48hr</time_frame>
    <description>from entry of PACU to go general ward</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postoperative pain score</measure>
    <time_frame>at postoperative 30minutes, 6hours, 24hours</time_frame>
    <description>postoperative pain score measured by 11-point NRS(numerical rating scale) score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postoperative rescue drug</measure>
    <time_frame>perioperative - until 72hr</time_frame>
    <description>administration of analgesic drug and anti-emetic drug for postoperative management</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hospital stay</measure>
    <time_frame>preoperative - until discharge (usually 48 hr to 72hr)</time_frame>
    <description>days of hospital stay</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Neuromuscular Blockade Reversal Agent</condition>
  <condition>Sugammadex</condition>
  <condition>Neostigmine</condition>
  <condition>Quality of Recovery</condition>
  <condition>Laparoscopic Cholecystectomy</condition>
  <arm_group>
    <arm_group_label>sugammadex</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>sugammadex 2mg/kg or 4mg/kg according to Train-of-four count (TOF 0 : 4mg/kg, TOF 1-4 : 2mg/kg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>neostigmine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>with glycopyrrolate 0.4mg, neostigmine 0.02mg/kg or 0.04mg/kg or 0.05mg/kg according to Train-of-four count (TOF 0 : wait until TOF 2, TOF2-3: 0.05mg/kg, TOF4: 0.04mg/kg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex</intervention_name>
    <description>sugammadex 2mg/kg or 4mg/kg according to Train-of-four count (TOF 0 : 4mg/kg, TOF 1-4 : 2mg/kg)</description>
    <arm_group_label>sugammadex</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neostigmine</intervention_name>
    <description>with glycopyrrolate 0.4mg, neostigmine 0.02mg/kg or 0.04mg/kg or 0.05mg/kg according to Train-of-four count (TOF 0 : wait until TOF 2, TOF2-3: 0.05mg/kg, TOF4: 0.04mg/kg)</description>
    <arm_group_label>neostigmine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients who underwent laparoscopic cholecystectomy aged 20-70

        Exclusion Criteria:

          -  neuromuscular disease

          -  allergy to rocuronium, sugammadex, neostigmine

          -  cognitive impairment ( disable to answer the questionnaire )

          -  refuse to participate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jiwon Han, Ms</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Bundang Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jiwon Han, Ms</last_name>
    <phone>82-10-3447-1988</phone>
    <email>hanjiwon@snubh.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ah-young Oh, professor</last_name>
    <phone>82-31-787-7506</phone>
    <email>oay1@snubh.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiwon Han, Ms</last_name>
      <phone>82-10-3447-1988</phone>
      <email>hanjiwon@snubh.org</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Stark PA, Myles PS, Burke JA. Development and psychometric evaluation of a postoperative quality of recovery score: the QoR-15. Anesthesiology. 2013 Jun;118(6):1332-40. doi: 10.1097/ALN.0b013e318289b84b.</citation>
    <PMID>23411725</PMID>
  </reference>
  <reference>
    <citation>Hristovska AM, Duch P, Allingstrup M, Afshari A. Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults. Cochrane Database Syst Rev. 2017 Aug 14;8:CD012763. doi: 10.1002/14651858.CD012763. Review.</citation>
    <PMID>28806470</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 1, 2020</study_first_submitted>
  <study_first_submitted_qc>April 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2020</study_first_posted>
  <last_update_submitted>April 1, 2020</last_update_submitted>
  <last_update_submitted_qc>April 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Bundang Hospital</investigator_affiliation>
    <investigator_full_name>JiWon Han</investigator_full_name>
    <investigator_title>clinical instructor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neostigmine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

